- Home
- UHT vs KROS Comparison
UHT vs KROS Comparison
Compare UHT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHT
- KROS
- Stock Information
- Founded
- UHT 1986
- KROS 2015
- Country
- UHT United States
- KROS United States
- Employees
- UHT N/A
- KROS N/A
- Industry
- UHT Real Estate Investment Trusts
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- UHT Real Estate
- KROS Health Care
- Exchange
- UHT Nasdaq
- KROS Nasdaq
- Market Cap
- UHT 566.7M
- KROS 565.0M
- IPO Year
- UHT N/A
- KROS 2020
- Fundamental
- Price
- UHT $40.33
- KROS $15.21
- Analyst Decision
- UHT
- KROS Buy
- Analyst Count
- UHT 0
- KROS 14
- Target Price
- UHT N/A
- KROS $20.56
- AVG Volume (30 Days)
- UHT 65.3K
- KROS 478.8K
- Earning Date
- UHT 10-23-2025
- KROS 08-06-2025
- Dividend Yield
- UHT 7.32%
- KROS N/A
- EPS Growth
- UHT N/A
- KROS N/A
- EPS
- UHT 1.30
- KROS 0.47
- Revenue
- UHT $99,952,000.00
- KROS $232,844,000.00
- Revenue This Year
- UHT $3.87
- KROS $5,579.44
- Revenue Next Year
- UHT N/A
- KROS N/A
- P/E Ratio
- UHT $30.98
- KROS $32.47
- Revenue Growth
- UHT 0.31
- KROS 85820.30
- 52 Week Low
- UHT $34.56
- KROS $9.12
- 52 Week High
- UHT $47.30
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- UHT 55.61
- KROS 57.93
- Support Level
- UHT $40.06
- KROS $14.57
- Resistance Level
- UHT $41.13
- KROS $15.83
- Average True Range (ATR)
- UHT 0.65
- KROS 0.63
- MACD
- UHT 0.22
- KROS 0.09
- Stochastic Oscillator
- UHT 76.92
- KROS 74.04
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.